Inventiva S.A Net Assets
Inventiva S.A net assets. Based on the latest financial reports, Inventiva S.A (IVA) has net assets worth €-28.52 Million EUR (≈ $-33.35 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€249.51 Million ≈ $291.70 Million USD) and total liabilities (€278.03 Million ≈ $325.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IVA year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-28.52 Million |
| % of Total Assets | -11.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | -132.1% |
| 10-Year Change | -179.84% |
| Growth Volatility | 82.35 |
Net Assets of Inventiva S.A (2013–2025)
Net assets of Inventiva S.A from 2013 to 2025. This chart illustrates how Inventiva S.A's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Inventiva S.A to measure how much of total assets are equity-financed.
Annual Net Assets for Inventiva S.A (2013–2025)
The table below shows the annual net assets of Inventiva S.A from 2013 to 2025. For live market cap and overall valuation, see market cap of Inventiva S.A.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-28.52 Million ≈ $-33.35 Million |
+73.26% |
| 2024-12-31 | €-106.65 Million ≈ $-124.68 Million |
-232.95% |
| 2023-12-31 | €-32.03 Million ≈ $-37.45 Million |
-170.43% |
| 2022-12-31 | €45.48 Million ≈ $53.17 Million |
-48.83% |
| 2021-12-31 | €88.87 Million ≈ $103.89 Million |
-20.09% |
| 2020-12-31 | €111.21 Million ≈ $130.02 Million |
+168.68% |
| 2019-12-31 | €41.39 Million ≈ $48.39 Million |
-32.80% |
| 2018-12-31 | €61.60 Million ≈ $72.01 Million |
-3.77% |
| 2017-12-31 | €64.01 Million ≈ $74.83 Million |
+79.18% |
| 2016-12-31 | €35.72 Million ≈ $41.76 Million |
-16.48% |
| 2015-12-31 | €42.77 Million ≈ $50.00 Million |
-16.96% |
| 2014-12-31 | €51.51 Million ≈ $60.22 Million |
-12.72% |
| 2013-12-31 | €59.01 Million ≈ $68.99 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Inventiva S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34700318200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Inventiva S.A Net Assets Breakdown (December 2025)
Inventiva S.A net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €1.93 Million | % |
| Other Comprehensive Income | €-204.55 Million | % |
| Other Components | €528.23 Million | % |
| Total Equity | €-28.52 Million | 100.00% |
Inventiva S.A Competitors by Market Cap
The table below lists competitors of Inventiva S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Focused Photonics Hangzhou Inc
SHE:300203
|
$772.21 Million |
|
Tejas Networks Limited
NSE:TEJASNET
|
$772.40 Million |
|
Guangzhou Hengyun Enterprises Holding Ltd
SHE:000531
|
$772.62 Million |
|
Canadian General Investments Ltd
TO:CGI
|
$772.64 Million |
|
Zhejiang Zhaofeng Mechanical and Electronic Co Ltd
SHE:300695
|
$771.96 Million |
|
Hangzhou Advance Gearbox Group Co Ltd
SHG:601177
|
$771.92 Million |
|
Railtel Corporation Of India Limited
NSE:RAILTEL
|
$771.91 Million |
|
Orient International Enterprise Ltd
SHG:600278
|
$771.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inventiva S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -106,646,000 to -28,522,000, a change of 78,124,000.
- Net loss of 354,138,000 reduced equity.
- New share issuances of 206,441,000 increased equity.
- Other comprehensive income decreased equity by 31,995,000.
- Other factors increased equity by 257,816,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-354.14 Million | -1241.63% |
| Share Issuances | €206.44 Million | +723.8% |
| Other Comprehensive Income | €-32.00 Million | -112.18% |
| Other Changes | €257.82 Million | +903.92% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Inventiva S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | €5.88 | €3.18 | x |
| 2014-12-31 | €5.14 | €3.18 | x |
| 2015-12-31 | €4.26 | €3.18 | x |
| 2016-12-31 | €2.27 | €3.18 | x |
| 2017-12-31 | €4.13 | €3.18 | x |
| 2018-12-31 | €3.00 | €3.18 | x |
| 2019-12-31 | €1.76 | €3.18 | x |
| 2020-12-31 | €3.28 | €3.18 | x |
| 2021-12-31 | €2.27 | €3.18 | x |
| 2022-12-31 | €1.10 | €3.18 | x |
| 2023-12-31 | €-0.71 | €3.18 | x |
| 2024-12-31 | €-1.78 | €3.18 | x |
| 2025-12-31 | €-0.15 | €3.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inventiva S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7899.58%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-32.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -12.09% | -232.82% | 0.04x | 1.48x | €-13.04 Million |
| 2014 | -14.55% | -228.26% | 0.04x | 1.42x | €-12.64 Million |
| 2015 | -20.63% | -181.00% | 0.08x | 1.42x | €-13.10 Million |
| 2016 | -19.72% | -74.59% | 0.19x | 1.37x | €-10.62 Million |
| 2017 | -26.92% | -264.22% | 0.09x | 1.16x | €-23.63 Million |
| 2018 | -54.57% | -1051.49% | 0.04x | 1.30x | €-39.78 Million |
| 2019 | -73.01% | -431.85% | 0.12x | 1.38x | €-34.36 Million |
| 2020 | -28.43% | -8500.81% | 0.00x | 1.25x | €-42.74 Million |
| 2021 | -55.85% | -1183.50% | 0.03x | 1.37x | €-58.52 Million |
| 2022 | -119.35% | -445.64% | 0.10x | 2.55x | €-58.82 Million |
| 2023 | 0.00% | -631.84% | 0.25x | 0.00x | €-107.22 Million |
| 2024 | 0.00% | -1251.10% | 0.12x | 0.00x | €-173.55 Million |
| 2025 | 0.00% | -7899.58% | 0.02x | 0.00x | €-351.29 Million |
Industry Comparison
This section compares Inventiva S.A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,337,853
- Average return on equity (ROE) among peers: -92.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inventiva S.A (IVA) | €-28.52 Million | -12.09% | N/A | $771.98 Million |
| Abionyx Pharma SA (ABNX) | $7.92 Million | -44.41% | 0.87x | $66.65 Million |
| Abivax SA (ABVX) | $4.67 Million | -803.57% | 14.26x | $8.06 Billion |
| Adocia (ADOC) | $-12.97 Million | 0.00% | 0.00x | $69.26 Million |
| Aelis Farma SA (AELIS) | $10.12 Million | -73.71% | 0.95x | $11.52 Million |
| Biophytis S.A. (ALBPS) | $-409.32K | 0.00% | 0.00x | $1.52 Million |
| Cellectis (ALCLS) | $6.40 Million | 0.00% | 0.20x | $88.25 Million |
| Advicenne (ALDVI) | $-19.07 Million | 0.00% | 0.00x | $11.01 Million |
| Genoway (ALGEN) | $17.38 Million | 9.02% | 0.83x | $29.86 Million |
| Integragen (ALINT) | $1.76 Million | -14.58% | 2.14x | $579.30K |
| Medesis Pharma SA (ALMDP) | $-2.42 Million | 0.00% | 0.00x | $1.80 Million |
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more